SG11202106214YA - Novel anti-ccr8 antibody - Google Patents
Novel anti-ccr8 antibodyInfo
- Publication number
- SG11202106214YA SG11202106214YA SG11202106214YA SG11202106214YA SG11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA
- Authority
- SG
- Singapore
- Prior art keywords
- novel anti
- ccr8 antibody
- ccr8
- antibody
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018245044 | 2018-12-27 | ||
| JP2019099923 | 2019-05-29 | ||
| PCT/JP2019/051603 WO2020138489A1 (en) | 2018-12-27 | 2019-12-27 | Novel anti-ccr8 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106214YA true SG11202106214YA (en) | 2021-07-29 |
Family
ID=71128288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106214YA SG11202106214YA (en) | 2018-12-27 | 2019-12-27 | Novel anti-ccr8 antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220064312A1 (en) |
| EP (1) | EP3903817A4 (en) |
| JP (2) | JP6894086B2 (en) |
| KR (1) | KR20210108996A (en) |
| CN (1) | CN113260381A (en) |
| AU (1) | AU2019415395A1 (en) |
| BR (1) | BR112021011431A2 (en) |
| CA (1) | CA3124332A1 (en) |
| MX (1) | MX2021007576A (en) |
| SG (1) | SG11202106214YA (en) |
| TW (1) | TW202039575A (en) |
| WO (1) | WO2020138489A1 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018181425A1 (en) | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | Medicinal composition for treating cancer |
| TW202039575A (en) | 2018-12-27 | 2020-11-01 | 日商鹽野義製藥股份有限公司 | Novel anti-ccr8 antibody |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| AU2021244200A1 (en) | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| TW202216771A (en) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | Ccr8 antibodies for therapeutic applications |
| US20230256092A1 (en) | 2020-06-30 | 2023-08-17 | Shionogi & Co., Ltd. | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| WO2022081718A1 (en) * | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| AU2021277712B2 (en) | 2020-10-16 | 2023-05-25 | LaNova Medicines Limited | Anti-CCR8 monoclonal antibodies and uses thereof |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| EP4267621A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Murine cross-reactive human ccr8 binders |
| CA3206304A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Human ccr8 binders |
| EP4267618A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Non-blocking human ccr8 binders |
| CN114805569A (en) * | 2021-01-29 | 2022-07-29 | 北京伟峰益民科技有限公司 | Anti-human CCL1 antibody and application thereof |
| WO2022211046A1 (en) | 2021-03-31 | 2022-10-06 | 塩野義製薬株式会社 | Chimeric antigen receptor that recognizes ccr8 as antigen |
| EP4347655A1 (en) * | 2021-06-04 | 2024-04-10 | Amgen Inc. | Anti-ccr8 antibodies and uses thereof |
| IL308809A (en) * | 2021-06-04 | 2024-01-01 | Amgen Res Munich Gmbh | T cell engager molecules and uses thereof |
| TW202309097A (en) | 2021-07-14 | 2023-03-01 | 美商建南德克公司 | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
| WO2023010054A1 (en) * | 2021-07-27 | 2023-02-02 | Abbvie Inc. | Anti-ccr8 antibodies |
| IL310938A (en) * | 2021-08-20 | 2024-04-01 | Hifibio Hk Ltd | Anti-ccr8 antibodies and uses thereof |
| TW202330504A (en) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | Pyridizin-3(2h)-one derivatives |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| TW202342533A (en) * | 2021-12-02 | 2023-11-01 | 中國大陸商再鼎醫藥（上海）有限公司 | Ccr8 antigen binding unit and uses thereof |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023116880A1 (en) * | 2021-12-23 | 2023-06-29 | Concept To Medicine Biotech Co., Ltd. | Anti-ccr8 antibodies and uses thereof |
| US20230279130A1 (en) * | 2022-01-14 | 2023-09-07 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN116789820A (en) * | 2022-03-18 | 2023-09-22 | 北京天诺健成医药科技有限公司 | Development and application of novel immunomodulator |
| TW202400138A (en) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d modulating compounds |
| WO2023206350A1 (en) * | 2022-04-29 | 2023-11-02 | Analytical Biosciences Shanghai Limited | Anti-ccr8 antibodies and uses thereof |
| WO2023219147A1 (en) * | 2022-05-13 | 2023-11-16 | 塩野義製薬株式会社 | Novel anti-ccr8 antibodies for detecting ccr8 |
| WO2023230473A1 (en) | 2022-05-24 | 2023-11-30 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024008110A1 (en) * | 2022-07-07 | 2024-01-11 | 四川思柏沃生物技术有限公司 | Anti-ccr8 antibody and use thereof |
| WO2024027823A1 (en) * | 2022-08-04 | 2024-02-08 | Beigene, Ltd. | Anti-ccr8 antibodies and methods of use |
| WO2024052517A2 (en) | 2022-09-09 | 2024-03-14 | Bayer Aktiengesellschaft | Medical use of ccr8 antibodies and dosing schedule |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0729976A1 (en) | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
| AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| IL129164A (en) | 1996-09-26 | 2007-05-15 | Chugai Pharmaceutical Co Ltd | Antibody against human parathormone related peptides |
| AU8669598A (en) * | 1997-07-29 | 1999-02-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chemokine receptor ccr8 dna and uses thereof |
| JP2001523446A (en) * | 1997-11-13 | 2001-11-27 | シェーリング コーポレイション | Th2 cell depletion, compositions, methods |
| US6762341B2 (en) * | 2000-02-10 | 2004-07-13 | Schering Corporation | Uses of mammalian CCR8 receptors and related reagents |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2013131010A2 (en) * | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| JP7358047B2 (en) * | 2016-05-16 | 2023-10-10 | チェックマブ エス．アール．エル． | Markers selectively deregulated in tumor-infiltrating regulatory T cells |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| WO2018181425A1 (en) * | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | Medicinal composition for treating cancer |
| WO2019157098A1 (en) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| TW202039575A (en) | 2018-12-27 | 2020-11-01 | 日商鹽野義製藥股份有限公司 | Novel anti-ccr8 antibody |
-
2019
- 2019-12-27 TW TW108148111A patent/TW202039575A/en unknown
- 2019-12-27 AU AU2019415395A patent/AU2019415395A1/en active Pending
- 2019-12-27 CA CA3124332A patent/CA3124332A1/en active Pending
- 2019-12-27 US US17/418,417 patent/US20220064312A1/en active Pending
- 2019-12-27 SG SG11202106214YA patent/SG11202106214YA/en unknown
- 2019-12-27 CN CN201980086253.6A patent/CN113260381A/en active Pending
- 2019-12-27 JP JP2020538152A patent/JP6894086B2/en active Active
- 2019-12-27 EP EP19905033.7A patent/EP3903817A4/en active Pending
- 2019-12-27 BR BR112021011431A patent/BR112021011431A2/en unknown
- 2019-12-27 MX MX2021007576A patent/MX2021007576A/en unknown
- 2019-12-27 WO PCT/JP2019/051603 patent/WO2020138489A1/en active Application Filing
- 2019-12-27 KR KR1020217023411A patent/KR20210108996A/en unknown
-
2021
- 2021-03-05 JP JP2021034895A patent/JP7452818B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020138489A1 (en) | 2020-07-02 |
| KR20210108996A (en) | 2021-09-03 |
| JP7452818B2 (en) | 2024-03-19 |
| AU2019415395A1 (en) | 2021-07-15 |
| US20220064312A1 (en) | 2022-03-03 |
| EP3903817A4 (en) | 2022-08-17 |
| JPWO2020138489A1 (en) | 2021-02-18 |
| JP2021101710A (en) | 2021-07-15 |
| EP3903817A1 (en) | 2021-11-03 |
| MX2021007576A (en) | 2021-08-24 |
| BR112021011431A2 (en) | 2021-11-23 |
| CN113260381A (en) | 2021-08-13 |
| JP6894086B2 (en) | 2021-06-23 |
| CA3124332A1 (en) | 2020-07-02 |
| TW202039575A (en) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| IL279321A (en) | Anti-sirpα antibody | |
| IL280780A (en) | Anti-tigit antibodies | |
| IL279352A (en) | Il-11ra antibodies | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| IL273393A (en) | Novel anti-cd3epsilon antibodies | |
| IL277030A (en) | Antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| IL284584A (en) | Anti-tigit antibodies | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| GB201817172D0 (en) | Antibody | |
| ZA202108836B (en) | Anti-epha4 antibody | |
| GB201905150D0 (en) | Ant-ige antibodies | |
| GB201806084D0 (en) | Antibodies | |
| GB201917480D0 (en) | Antibodies | |
| GB201900732D0 (en) | Antibodies | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201813597D0 (en) | Antibody | |
| GB201919062D0 (en) | Antibody | |
| GB201809945D0 (en) | Antibody | |
| GB201819952D0 (en) | Antibodies | |
| GB201912008D0 (en) | Antibody |